Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system

Proteomics

Volumn 13, Issue 15, 2013, Pages 2351-2360

  Arai, Kazuya ^a,b   Sakamoto, Ruriko ^a,b   Kubota, Daisuke ^a   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b SCIVAX Corporation   (Japan)

Author keywords

2DE; Cathepsin D; Chemotherapy; Osteosarcoma; Spheroid culture

Indexed keywords

CATHEPSIN D; DOXORUBICIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CULTURE; CONTROLLED STUDY; DATA BASE; GENOME; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOLECULAR PATHOLOGY; MONOLAYER CULTURE; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; SPHEROID CELL; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

EID: 84881255714     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300053     Document Type: Article

References (48)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
2. Eilber, F., Giuliano, A., Eckardt, J., Patterson, K. et al., Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J. Clin. Oncol. 1987, 5, 21-26.
3. Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A. et al., The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med. 1986, 314, 1600-1606.
4. Bielack, S., Carrle, D., Jost, L., Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2008, 19(Suppl 2), ii94-96.
5. Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C. et al., Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982, 49, 1221-1230.
6. Hogendoorn, P. C., Athanasou, N., Bielack, S., De Alava, E. et al., Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21(Suppl 5), v204-213.
7. Ferrari, S., Ruggieri, P., Cefalo, G., Tamburini, A. et al., Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J. Clin. Oncol. 2012, 30, 2112-2118.
8. Poland, J., Schadendorf, D., Lage, H., Schnolzer, M. et al., Study of therapy resistance in cancer cells with functional proteome analysis. Clin. Chem. Lab. Med. 2002, 40, 221-234.
9. Skalnikova, H., Martinkova, J., Hrabakova, R., Halada, P. et al., Cancer drug-resistance and a look at specific proteins: Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and HSP70/90 organizing protein in proteomics clinical application. J. Proteome Res. 2011, 10, 404-415.
10. de Saldanha da Gama Fischer, J., Costa Carvalho, P., da Fonseca, C. O., Liao, L. et al., Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol. J. Proteome Res. 2011, 10, 153-160.
11. Chabner, B. A., Roberts, T. G., Jr., Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5, 65-72.
12. Weisenthal, L. M., Antineoplastic drug screening belongs in the laboratory, not in the clinic. J. Natl. Cancer Inst. 1992, 84, 466-469.
13. Harma, V., Virtanen, J., Makela, R., Happonen, A. et al., A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 2010, 5, e10431.
14. Nyga, A., Cheema, U., Loizidou, M., 3D tumour models: novel in vitro approaches to cancer studies. J. Cell. Commun. Signal 2011, 5, 239-248.
15. Griffith, L. G., Swartz, M. A., Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell Biol. 2006, 7, 211-224.
16. Pampaloni, F., Reynaud, E. G., Stelzer, E. H., The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 2007, 8, 839-845.
17. Yamada, K. M., Cukierman, E., Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130, 601-610.
18. Sutherland, R. M., Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988, 240, 177-184.
19. Weigelt, B., Lo, A. T., Park, C. C., Gray, J. W. et al., HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res. Treat 2010, 122, 35-43.
20. Karlsson, H., Fryknas, M., Larsson, R., Nygren, P., Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp. Cell Res. 2012, 318, 1577-1585.
21. Chitcholtan, K., Sykes, P. H., Evans, J. J., The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. J. Transl. Med. 2012, 10, 38, 1-16.
22. Mintz, M. B., Sowers, R., Brown, K. M., Hilmer, S. C. et al., An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005, 65, 1748-1754.
23. Ochi, K., Daigo, Y., Katagiri, T., Nagayama, S. et al., Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int. J. Oncol. 2004, 24, 647-655.
24. Gougelet, A., Pissaloux, D., Besse, A., Perez, J. et al., Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int. J. Cancer 2011, 129, 680-690.
25. Kikuta, K., Tochigi, N., Saito, S., Shimoda, T. et al., Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. Proteomics Clin. Appl. 2010, 4, 560-567.
26. Borys, D., Canter, R. J., Hoch, B., Martinez, S. R. et al., P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy. Hum. Pathol. 2012, 43, 1948-1954.
27. Chen, Y., Yang, Y., Yuan, Z., Wang, C., Shi, Y., Predicting chemosensitivity in osteosarcoma prior to chemotherapy: an investigational study of biomarkers with immunohistochemistry. Oncol. Lett. 2012, 3, 1011-1016.
28. Windus, L. C., Kiss, D. L., Glover, T., Avery, V. M., In vivo biomarker expression patterns are preserved in 3D cultures of Prostate Cancer. Exp. Cell Res. 2012, 318, 2507-2519.
29. Ghosh, A. K., Hurd, T., Hildebrandt, F., 3D spheroid defects in NPHP knockdown cells are rescued by the somatostatin receptor agonist octreotide. Am. J. Physiol. Renal. Physiol. 2012, 303, F1225-1229.
30. Lopez, J., Poitevin, A., Mendoza-Martinez, V., Perez-Plasencia, C., Garcia-Carranca, A., Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer 2012, 12, 48, 1-14.
31. Fogh, J., Fogh, J. M., Orfeo, T., One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 1977, 59, 221-226.
32. Roberts, W. M., Douglass, E. C., Peiper, S. C., Houghton, P. J. et al., Amplification of the GLI gene in childhood sarcomas. Cancer Res. 1989, 49, 5407-5413.
33. Rhim, J. S., Cho, H. Y., Huebner, R. J., Non-producer human cells induced by murine sarcoma virus. Int. J. Cancer 1975, 15, 23-29.
34. McAllister, R. M., Gardner, M. B., Greene, A. E., Bradt, C. et al., Cultivation in vitro of cells derived from a human osteosarcoma. Cancer 1971, 27, 397-402.
35. Billiau, A., Edy, V. G., Heremans, H., Van Damme, J. et al., Human interferon: mass production in a newly established cell line, MG-63. Antimicrob. Agents Chemother. 1977, 12, 11-15.
36. Rhim, J. S., Park, D. K., Arnstein, P., Huebner, R. J. et al., Transformation of human cells in culture by N-methyl-N'-nitro-N-nitrosoguanidine. Nature 1975, 256, 751-753.
37. King, M. P., Attardi, G., Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989, 246, 500-503.
38. Sonobe, H., Mizobuchi, H., Manabe, Y., Furihata, M. et al., Establishment and characterization of a cell line, HS-Os-1 derived from an osteoblastic type of human osteosarcoma. Hum. Cell 1990, 3, 148-151.
39. Hotta, T., Motoyama, T., Watanabe, H., Three human osteosarcoma cell lines exhibiting different phenotypic expressions. Acta Pathol. Jpn. 1992, 42, 595-603.
40. Yoshii, Y., Waki, A., Yoshida, K., Kakezuka, A. et al., The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation. Biomaterials 2011, 32, 6052-6058.
41. Kondo, T., Mihara, K., Inoue, Y., Iijima, M. et al., Two-dimensional electrophoretic analysis of down-regulated proteins in human fibroblasts immortalized by treatment with either 4-nitroquinoline 1-oxide or 60Co gamma rays. Electrophoresis 1995, 16, 1067-1073.
42. Fujii, K., Kondo, T., Yokoo, H., Yamada, T. et al., Protein expression pattern distinguishes different lymphoid neoplasms. Proteomics 2005, 5, 4274-4286.
43. Kondo, T., Hirohashi, S., Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nature Protocols 2007, 1, 2940-2956.
44. Kondo, T., Cancer proteome-expression database: Genome Medicine Database of Japan Proteomics. Expert Rev. Proteomics 2010, 7, 21-27.
45. Sagulenko, V., Muth, D., Sagulenko, E., Paffhausen, T. et al., Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death. Carcinogenesis 2008, 29, 1869-1877.
46. Chen, S., Chen, C. M., Yu, K. D., Yang, W. T. et al., A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer. J. Surg. Oncol. 2012, 105, 577-585.
47. Leto, G., Tumminello, F. M., Crescimanno, M., Flandina, C. et al., Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications. Clin. Exp. Metastasis 2004, 21, 91-106.
48. Hortobagyi, G. N., Comprehensive management of locally advanced breast cancer. Cancer 1990, 66, 1387-1391.